NCT00233675已完成3 期
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder
Cephalon51 个研究点 分布在 1 个国家开始时间: 2003年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 51
研究概览
简要总结
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Not available at time of registration
排除标准
- 未提供
研究者
研究点 (51)
Loading locations...
相似试验
终止
3 期
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGSEpilepsyNCT01668654GlaxoSmithKline4
已完成
3 期
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.Anxiety DisordersNCT00214994Cephalon
已完成
3 期
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialEpilepsyNCT00310375GlaxoSmithKline181
尚未招募
1 期
Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc DiseaseDegenerative Disc DiseaseNCT06144970Kolon TissueGene, Inc.24
已完成
4 期
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and InsulinDiabetes Mellitus, Type 2NCT01341717Jothydev's Diabetes and Research Centre440